CytoCore, Inc. (OTCBB:CYCR), a biopharmaceutical research and medical device company focused on early detection and treatment of reproductive-tract cancers, reported a loss of $.02 per share for the third quarter vs. a loss of $.03/share for the same period a year ago. The company continued to improve its balance sheet by reducing the liability balance to $2.5 million with a reduction of $1.613 million or 40% from the $4.13 million of a year earlier. Much of this reduction resulted from cashless settlements. The company is optimistic about achieving a balance for the liabilities of approximately $750,000 by year end.
